The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
Store reconstituted solution at 28C
Kaina, Abrogation of cellular senescence induced by temozolomide in glioblastoma cells: search for senolytics
55.8% reduction in the appearance of wrinkle volume in a randomized, double-blind trial over 8 weeks Pickart et al., PMC 2018 70% of volunteers showed visibly improved skin firmness, outperforming vitamin C and retinoic acid comparators Pickart et al., multiple publications 32.8% reduction in the visible appearance of wrinkle depth (double-blind, 8 weeks) Published cosmetic science research 40+ years of published research since GHK-Cu was first identified in human plasma in 1973 Discovered by Dr